Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy

References

• KaminskyLSZhangZYHuman P450 metabolism of warfarinPharmacol Ther199773167749014207
   PubMed Web of Science ®Google Scholar
• NatarajanSPondeCKRajaniRMEffect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patientsPharmacol Rep20136551375138224399734
   PubMed Web of Science ®Google Scholar
• RaviñaEThe Evolution of Drug Discovery: From Traditional Medicines to Modern DrugsWeinheim cityJohn Wiley & Sons2011
   Google Scholar
• HirshJDalenJEAndersonDROral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic rangeChest19981145 Suppl445S4699822057
   PubMed Web of Science ®Google Scholar
• YinTMiyataTWarfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – rationale and perspectivesThromb Res2007120111017161452
   PubMed Web of Science ®Google Scholar
• GageBFLeskoLJPharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJ Thromb Thrombolysis2008251455117906972
   PubMed Web of Science ®Google Scholar
• HirshJDalenJAndersonDROral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic rangeChest20011191 Suppl8S2111157640
   PubMed Web of Science ®Google Scholar
• PiatkovIRochesterCJonesTBoyagesSWarfarin toxicity and individual variability – clinical caseToxins20102112584259222069565
   PubMed Web of Science ®Google Scholar
• LiCSchwarzUIRitchieMDRodenDMSteinCMKurnikDRelative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapyBlood2009113173925393019074728
   PubMed Web of Science ®Google Scholar
• HughesDAPirmohamedMWarfarin pharmacogenetics: economic considerationsPharmacoeconomics2007251189990217960949
   PubMed Web of Science ®Google Scholar
• RendicSSummary of information on human CYP enzymes: human P450 metabolism dataDrug Metab Rev2002341-28344811996015
   PubMed Web of Science ®Google Scholar
• ZhouSFZhouZWYangLPCaiJPSubstrates, inducers, inhibitors and structure–activity relationships of human cytochrome P450 2C9 and implications in drug developmentCurr Med Chem200916273480367519515014
   PubMed Web of Science ®Google Scholar
• WangDSunXGongYCYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human liversDrug Metab Dispos201240588489122289258
   PubMed Web of Science ®Google Scholar
• MlynarskyLBejarano-AchacheIMuszkatMCaracoYFactor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriersEur J Clin Pharmacol201268561762722071881
   PubMed Web of Science ®Google Scholar
• GreiseneggerSWeberMFunkMPolymorphisms in the coagulation factor VII gene and risk of primary intracerebral hemorrhageEur J Neurol200714101098110117880564
   PubMed Web of Science ®Google Scholar
• MoXHaoYYangXChenSLuXGuDAssociation between polymorphisms in the coagulation factor VII gene and coronary heart disease risk in different ethnicities: a meta-analysisBMC Med Genet201112110721838885
   PubMed Web of Science ®Google Scholar
• Di CastelnuovoAD’OrazioAAmoreCFalangaADonatiMBIacovielloLThe decanucleotide insertion/deletion polymorphism in the promoter region of the coagulation factor VII gene and the risk of familial myocardial infarctionThromb Res200098191710706929
   PubMed Web of Science ®Google Scholar
• GirelliDRussoCFerraresiPPolymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery diseaseN Engl J Med20003431177478010984565
   PubMed Web of Science ®Google Scholar
• WangXLWangJMcCredieRMWilckenDEPolymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery diseaseArterioscler Thromb Vasc Biol19971722462519081677
   PubMed Web of Science ®Google Scholar
• ArdissinoDMannucciPMMerliniPAProthrombotic genetic risk factors in young survivors of myocardial infarctionBlood1999941465110381497
   PubMed Web of Science ®Google Scholar
• GageBFPharmacogenetics-based coumarin therapyHematology Am Soc Hematol Educ Program20061467473
   Google Scholar
• D’AndreaGD’AmbrosioRMargaglioneMOral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factorsBlood Rev200822312714018234403
   PubMed Web of Science ®Google Scholar
• HylekEMD’AntonioJEvans-MolinaCSheaCHenaultLEReganSTranslating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillationStroke20063741075108016527999
   PubMed Web of Science ®Google Scholar
• KuruvillaMGurk-TurnerCA review of warfarin dosing and monitoringProc (Bayl Univ Med Cent)200114330530616369639
   PubMedGoogle Scholar
• MarchettiGGemmatiDPatracchiniPPinottiMBernardiFPCR detection of a repeat polymorphism within the F7 geneNucleic Acids Res199119164570
   Web of Science ®Google Scholar
• SchellemanHChenJChenZDosing algorithms to predict warfarin maintenance dose in Caucasians and African AmericansClin Pharmacol Ther200884333233918596683
   PubMed Web of Science ®Google Scholar
• PirmohamedMBurnsideGErikssonNA randomized trial of genotype-guided dosing of warfarinN Engl J Med2013369242294230324251363
   PubMed Web of Science ®Google Scholar
• YuanHYChenJJLeeMTA novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivityHum Mol Genet200514131745175115888487
   PubMed Web of Science ®Google Scholar
• DalyAKPharmacogenomics of anticoagulants: steps toward personal dosageGenome Med2009111019348697
   PubMed Web of Science ®Google Scholar
• JonasDEMcLeodHLGenetic and clinical factors relating to warfarin dosingTrends Pharmacol Sci200930737538619540002
   PubMed Web of Science ®Google Scholar
• CaldwellMDBergRLZhangKQEvaluation of genetic factors for warfarin dose predictionClin Med Res20075181617456829
   PubMedGoogle Scholar
• ShikataEIeiriIIshiguroSAssociation of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gammaglutamyl carboxylase) gene variants with warfarin sensitivityBlood200410372630263514656880
   PubMed Web of Science ®Google Scholar
• KohnkeHSörlinKGranathGWadeliusMWarfarin dose related to apolipoprotein E (APOE) genotypeEur J Clin Pharmacol2005615–638138815952022
   PubMed Web of Science ®Google Scholar
• GageBFEbyCJohnsonJAUse of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarinClin Pharmacol Ther200884332633118305455
   PubMed Web of Science ®Google Scholar
• IacovielloLdi CastelnuovoAde KnijffPPolymorphisms in the coagulation factor VII gene and the risk of myocardial infarctionN Engl J Med1998338279859420338
   PubMed Web of Science ®Google Scholar